Treatment for diabetic macular edema in new patients
Part of Eyes & vision, Hormones & metabolism clinical trials.
This study tests a treatment for diabetic macular edema (swelling in the back of the eye caused by diabetes) in people who have not had eye injections before. It aims to see if the treatment can improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have type 1 or type 2 diabetes.
- Your vision in the study eye is between 20/32 and 20/320 (about 24 to 78 letters on an eye chart).
- You have not had any eye surgery, injections, or laser treatment in the study eye before.
- Your blood sugar control is stable (HbA1c less than 10%).
- You do not have other serious eye conditions like retinal detachment or advanced diabetic eye disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an eye injection called OLN324 for diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The treatment aims to improve vision and reduce swelling in the eye.
This study tests an experimental eye injection (OLN324) for people with diabetic macular edema, a condition where swelling in the back of the eye causes vision loss. The goal is to see if the injection can improve vision.
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
This trial tests whether combining a steroid implant (dexamethasone) with an anti-VEGF injection (aflibercept) works better than the injection alone for people with diabetic macular edema who haven't been treated yet. It aims to improve vision and reduce retinal swelling.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This study compares a new medication, tabirafusp tedromer, to an existing treatment, aflibercept, for people with diabetic macular edema (swelling in the back of the eye from diabetes). It may help if your DME hasn't improved or you're looking for a new option.
Hear when a new Diabetic Macular Edema (DME) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.